3T Biosciences launches $40M at solid tumors with TCR techTherapeuticsBay Area-based 3T Biosciences launched Thursday with a technology platform its leadership team believes can change the future of treatment for solid tumors and immune-mediated diseases. Read more August 25, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/08/Oaklandbaybridge-2022.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-08-25 09:36:592022-08-25 12:12:183T Biosciences launches $40M at solid tumors with TCR tech
